Biotech News

Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London

Lexicon Pharmaceuticals (LXRX)Lexicon PharmaceuticalsConference / presentation

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 8:00 a.m. GMT in London.

Related news

Lexicon Pharmaceuticals

Genetically Informed Drug Discovery Lexicon Pharmaceuticals uses human-genetic insights to discover and develop medicines for cardiometabolic and neurologic diseases. Sotagliflozin Franchise Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor. It is marketed as INPEFA for heart-failure-related indications, while the ZYNQUISTA application...

Recent company news

Stock data

Close
1.67 USD
Market cap
839.53M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States